Home

DBV Technologies S.A. - American Depositary Shares (DBVT)

7.7000
+1.2400 (19.20%)
NASDAQ · Last Trade: Apr 2nd, 9:23 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
Châtillon, France, March 27, 2025
By DBV Technologies S.A. · Via GlobeNewswire · March 27, 2025
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
Châtillon, France, March 24, 2025
By DBV Technologies S.A. · Via GlobeNewswire · March 24, 2025
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
Châtillon, France, February 25, 2025
By DBV Technologies S.A. · Via GlobeNewswire · February 25, 2025
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationChâtillon, France, January 13, 2025
By DBV Technologies S.A. · Via GlobeNewswire · January 13, 2025
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
Châtillon, France, January 8th, 2025
By DBV Technologies S.A. · Via GlobeNewswire · January 8, 2025
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
Châtillon, France, December 11th, 2024
By DBV Technologies S.A. · Via GlobeNewswire · December 11, 2024
Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · December 2, 2024
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, November 11, 2024
By DBV Technologies S.A. · Via GlobeNewswire · November 11, 2024
DBV Technologies Reports Third Quarter 2024 Financial Results
Châtillon, France, November 6, 2024
By DBV Technologies S.A. · Via GlobeNewswire · November 6, 2024
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
Investors in healthcare and biotech sectors should keep an eye on several prominent companies making strides in innovation, clinical trials, and global expansion. Modular Medical (NASDAQ: MODD), Cardiol Therapeutics (NASDAQ: CRDL) , DBV Technologies (NASDAQ: DBVT) , and Virax Biolabs (NASDAQ: VRAX) are key players to watch in the ever-evolving medical landscape. Each company has announced significant developments in technology, trials, and product distribution, solidifying their positions in the market.
Via AB Newswire · October 23, 2024
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
Châtillon, France, October 22, 2024
By DBV Technologies S.A. · Via GlobeNewswire · October 22, 2024
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
Châtillon, France, October 18, 2024
By DBV Technologies S.A. · Via GlobeNewswire · October 18, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · October 14, 2024
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
Châtillon, France, September 23, 2024
By DBV Technologies S.A. · Via GlobeNewswire · September 23, 2024
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Châtillon, France, September 4, 2024
By DBV Technologies S.A. · Via GlobeNewswire · September 4, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
By DBV Technologies S.A. · Via GlobeNewswire · August 2, 2024
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
Châtillon, France, July 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · July 30, 2024
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
Châtillon, France, July 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · July 30, 2024
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
Châtillon, France, July 29, 2024
By DBV Technologies S.A. · Via GlobeNewswire · July 29, 2024
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationMontrouge, France, July 8, 2024
By DBV Technologies S.A. · Via GlobeNewswire · July 8, 2024
DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Châtillon, France, June 5, 2024
By DBV Technologies S.A. · Via GlobeNewswire · June 5, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024
By DBV Technologies S.A. · Via GlobeNewswire · June 4, 2024
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, May 31, 2024
By DBV Technologies S.A. · Via GlobeNewswire · May 31, 2024
DBV Technologies to Participate in Upcoming EAACI 2024 Congress
Châtillon, France, May 30, 2024
By DBV Technologies S.A. · Via GlobeNewswire · May 30, 2024
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, May 17, 2024
By DBV Technologies S.A. · Via GlobeNewswire · May 17, 2024